ZA200608178B - Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins - Google Patents

Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins

Info

Publication number
ZA200608178B
ZA200608178B ZA200608178A ZA200608178A ZA200608178B ZA 200608178 B ZA200608178 B ZA 200608178B ZA 200608178 A ZA200608178 A ZA 200608178A ZA 200608178 A ZA200608178 A ZA 200608178A ZA 200608178 B ZA200608178 B ZA 200608178B
Authority
ZA
South Africa
Prior art keywords
modulation
polypeptide sequence
viral proteins
sequence involved
protein
Prior art date
Application number
ZA200608178A
Other languages
English (en)
Inventor
Renard Martial
Mangeney Marianne
Heidmann Thierry
Original Assignee
Roussy Inst Gustave
Centre Nat Rech Scient
Univ Paris Sud Xi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussy Inst Gustave, Centre Nat Rech Scient, Univ Paris Sud Xi filed Critical Roussy Inst Gustave
Publication of ZA200608178B publication Critical patent/ZA200608178B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA200608178A 2004-03-30 2005-03-30 Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins ZA200608178B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04290838 2004-03-30

Publications (1)

Publication Number Publication Date
ZA200608178B true ZA200608178B (en) 2008-10-29

Family

ID=34896141

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200608178A ZA200608178B (en) 2004-03-30 2005-03-30 Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins

Country Status (14)

Country Link
US (2) US8178657B2 (enExample)
EP (1) EP1732585B1 (enExample)
JP (1) JP5060284B2 (enExample)
CN (1) CN1961001B (enExample)
AT (1) ATE472334T1 (enExample)
AU (1) AU2005229411B2 (enExample)
BR (1) BRPI0509497B1 (enExample)
CA (1) CA2561376C (enExample)
DE (1) DE602005022056D1 (enExample)
ES (1) ES2347445T3 (enExample)
IL (1) IL178205A (enExample)
MX (1) MXPA06011272A (enExample)
WO (1) WO2005095442A1 (enExample)
ZA (1) ZA200608178B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9777044B2 (en) 2003-05-02 2017-10-03 Centre National De La Recherche Scientifique (Cnrs) GLUT-1 as a receptor for HTLV envelopes and its uses
EP2402447A1 (en) 2005-03-30 2012-01-04 Viroxis Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment
US20070185025A1 (en) * 2005-09-11 2007-08-09 The Trustees Of Columbia University In The City Of New York Filoviral immunosuppressive peptides and uses thereof
US20080299150A1 (en) * 2007-05-08 2008-12-04 Sankhia Corporation Method and system for processing immuno-competent cells in view of an antiviral therapy, and related therapeutic process
US8323891B2 (en) * 2008-08-01 2012-12-04 Claflin University miRNA triplex formations for the downregulation of viral replication
RU2008140688A (ru) * 2008-10-15 2010-04-20 Михаил Аркадьевич Шурдов (RU) Иммуносупрессивный пептид
WO2010079208A1 (en) 2009-01-09 2010-07-15 Centre National De La Recherche Scientifique New receptor binding ligands, their use in the detection of cells with biological interest
WO2011092199A1 (en) * 2010-01-26 2011-08-04 Institut Gustave Roussy Mutated xmrv env proteins in the immunosuppressive domain
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
WO2012035369A1 (en) * 2010-09-17 2012-03-22 Centre National De La Recherche Scientifique Method for the diagnosis and/or prognosis of inflammatory states
RS58289B1 (sr) * 2011-07-20 2019-03-29 Merial Ltd Rekombinantna vakcina protiv virusa mačje leukemije koja sadrži optimizovani gen omotača virusa mačje leukemije
US9636396B2 (en) 2011-12-07 2017-05-02 Centre National De La Recherche Scientifique Mutant human and simian immunodeficiency virus ENV proteins with reduced immunosuppressive properties
EP2788372B1 (en) * 2011-12-07 2019-07-10 Viroxis S.A.S. Mutated lentiviral env proteins and their use as drugs
CA2912354C (en) 2013-06-07 2023-01-24 Viroxis S.A.S. Mutated non-primate lentiviral env proteins and their use as drugs
JP6864364B2 (ja) * 2015-06-11 2021-04-28 学校法人慶應義塾 融合タンパク質又は複合タンパク質、細胞内送達用担体、部分ペプチド、細胞膜透過促進剤、ｄｎａ、及びベクター
CA2999792A1 (en) * 2015-10-01 2017-04-06 Magdalena Janina LASKA Use of human derived immunosuppressive proteins and peptides as medicaments
US11351247B2 (en) 2017-09-01 2022-06-07 Inprother Aps Vaccine for use in the prophylaxis and/or treatment of a disease
US20210403907A1 (en) 2018-09-18 2021-12-30 Vnv Newco Inc. Arc-based capsids and uses thereof
EP3852813A4 (en) 2018-09-18 2022-06-22 VNV Newco Inc. ARC-BASED CAPSIDS AND THEIR USES
US11129892B1 (en) 2020-05-18 2021-09-28 Vnv Newco Inc. Vaccine compositions comprising endogenous Gag polypeptides
US20240093233A1 (en) 2021-01-13 2024-03-21 Viroxis Measles-hiv or measles-htlv vaccine
EP4392053A4 (en) * 2021-08-23 2025-06-25 Gabet, Yankel COMPOSITIONS AND METHODS FOR THE TREATMENT OF BONE DISEASES OR CONDITIONS
WO2024218400A1 (en) 2023-04-21 2024-10-24 Inprother Aps Improved expression of surface-displayed antigens
CN121717880A (zh) * 2025-12-25 2026-03-24 中国海洋大学青岛海上丝路研究院 许氏平鲉内源性逆转录病毒包膜蛋白percomORF、慢病毒载体及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4822606A (en) 1986-04-07 1989-04-18 Duke University Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences
EP0377842B1 (en) 1988-12-13 1995-10-04 President And Fellows Of Harvard College Prototype FeLV isolates for use in disease models and vaccines
FR2771011B1 (fr) * 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
FR2780069B1 (fr) * 1998-06-23 2002-06-28 Inst Nat Sante Rech Med Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
WO2001031021A1 (en) * 1999-10-28 2001-05-03 Universite De Geneve Multiple sclerosis-related superantigen
CA2429755A1 (en) * 2000-12-11 2002-06-20 Tufts University Treatment and prevention of ebv infection and ebv-associated disorders
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition

Also Published As

Publication number Publication date
US8178657B2 (en) 2012-05-15
JP5060284B2 (ja) 2012-10-31
JP2008506357A (ja) 2008-03-06
ES2347445T3 (es) 2010-10-29
EP1732585A1 (en) 2006-12-20
ATE472334T1 (de) 2010-07-15
AU2005229411A1 (en) 2005-10-13
BRPI0509497B1 (pt) 2022-07-19
IL178205A (en) 2015-05-31
US20120189647A1 (en) 2012-07-26
US20080008683A1 (en) 2008-01-10
BRPI0509497A (pt) 2007-09-11
WO2005095442A8 (en) 2006-11-02
WO2005095442A1 (en) 2005-10-13
AU2005229411B2 (en) 2010-11-18
US8597657B2 (en) 2013-12-03
MXPA06011272A (es) 2007-04-17
DE602005022056D1 (de) 2010-08-12
CN1961001A (zh) 2007-05-09
CN1961001B (zh) 2012-09-05
CA2561376A1 (en) 2005-10-13
IL178205A0 (en) 2006-12-31
EP1732585B1 (en) 2010-06-30
CA2561376C (en) 2016-06-21

Similar Documents

Publication Publication Date Title
IL178205A0 (en) Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins
WO2005032487A3 (en) Angiotensin-converting enzyme-2 as a receptor for the sars coronavirus
SI1685243T1 (sl) Imortalizirane ptičje celične linije za produkcijo virusov
WO2006136084A8 (en) Fusion proteins of recombinant sars coronavirus structural proteins, their production and uses
EP2395078A3 (en) Covalent tethering of functional groups to proteins and substrates therefor
WO2009108274A3 (en) Methods and compositions for adeno-associated virus (aav) with hi loop mutations
EP2673289A1 (en) Viral vectors with modified transduction profiles and methods of making and using the same
IL187168A (en) Proteins or polypeptides which comprise two identical nanobodies against von willebrand factor, methods for their preparation, pharmaceutical compositions comprising them and their uses
DK1513937T3 (da) Fremgangsmåde til den samtidige produktion af multiple proteiner; vektorer og celler til anvendelse derved
WO2010132092A3 (en) Cytidine deaminase fusions and related methods
MY169472A (en) Refolding of recombinant proteins
MX2009010492A (es) Elementos de vector de expresion recombinante (reves) para mejorar la expresion de proteinas recombinantes en celulas huesped.
MX2022014162A (es) Proteínas de fusión de la proteína de la espícula del coronavirus estabilizadas.
MX2009006398A (es) Genotecas de proteinas de fusion de transferrina.
SG160424A1 (en) Compositions of influenza viral proteins and methods of use thereof
WO2006074233A3 (en) Polypeptides having nucleic acid binding activity and compositions and methods for nucleic acid amplification
WO2007053188A3 (en) Production of multivalent virus like particles
MX2009012326A (es) Peptidos de señalizacion.
WO2004024750A3 (en) Cd44-binding ligands
WO2005003315A3 (en) Compositions and methods for peptide-assisted transfection
DE60114018D1 (de) Von zellen präsentierte peptide
DE602005023181D1 (de) Lentivirusvektoren und deren verwendung
WO2007047504A3 (en) Natriuretic peptide modified transferrin fusion proteins
MX2010000232A (es) Metodos mejorados para la formacion de enlaces disulfuro.
WO2005002501A3 (en) Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same